Boston Scientific Watchmen Left Atrial Appendage Closure Atrial Fibrillation

Boston Scientific reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The data was supposed to be presented during the 2013 American College of Cardiology (ACC) meeting on March 9 as the lead-off late breaking trial. However, Boston Scientifc released information about the trial prior to ACC lifting the embargo. As a result of the embargo break, the presentation was pulled off the ACC agenda.

Medtronic Inc. announced it has received CE mark and will begin the European launch of the Attain Performa portfolio of quadripolar leads.

At the American College of Cardiology (ACC) conference, GE Healthcare unveiled DoseMap to alert interventional cardiologists to patient radiation exposure during longer procedures.

Accumetrics Verify Now ACC 2013 Antiplatelet Therapy Blood Testing Pharmaceutica

Accumetrics Inc. announced the presentation of a series of important data that solidifies the clinical utility of platelet reactivity testing. Real world outcomes data in high-risk patients receiving stents, a cost effectiveness analysis, and validation of a therapeutic window continue to demonstrate platelet reactivity as a critical element for improving the quality of care for the millions of patients on antiplatelet therapies worldwide.

AliveCor announced that its mobile Heart Monitor for iPhone is now available by prescription to enable patients to record their heart rhythm anytime, anywhere. The Heart Monitor, which makes home cardiac assessment quick and easy, is the first U.S. Food and Drug Administration (FDA)-cleared mobile device–based ECG monitor that is compatible with iPhone4 and 4S. The device was demonstrated at the ACC.13 annual meeting of the American College of Cardiology March 9 through March 11 in San Francisco.

Agfa HealthCare demonstrated its Impax CV Web+ solution at the American College of Cardiology's (ACC) 62nd Annual Scientific Session and Expo held in San Francisco from March 9-11. The technology transforms cardiovascular care delivery by providing physician access to cardiovascular images and reports regardless of location.

 

For better treatment planning during cardiac resynchronization therapy (CRT), Toshiba America Medical System Inc.’s Activation Imaging is the company’s latest addition to its 3-D Wall Motion Tracking software. Activation Imaging is an U.S. Food and Drug Administration (FDA)-cleared, proprietary technology available on the Aplio Artida cardiovascular ultrasound system.

 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now